In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of ARS Pharmaceuticals Inc (NASDAQ: SPRY) closed at $10.07 in the last session, down -5.53% from day before closing price of $10.66. In other words, the price has decreased by -$5.53 from its previous closing price. On the day, 1.39 million shares were traded. SPRY stock price reached its highest trading level at $10.7 during the session, while it also had its lowest trading level at $10.0.
Ratios:
We take a closer look at SPRY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.66.
On September 04, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $40.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 13 ’25 when Dorsey Brian sold 21,828 shares for $8.71 per share. The transaction valued at 190,050 led to the insider holds 10,789 shares of the business.
Chakma Justin sold 166,380 shares of SPRY for $1,476,147 on Nov 12 ’25. The Chief Business Officer now owns 0 shares after completing the transaction at $8.87 per share. On Nov 13 ’25, another insider, BRIAN T DORSEY, who serves as the Officer of the company, bought 21,828 shares for $8.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 995405440 and an Enterprise Value of 1872407040. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.97 while its Price-to-Book (P/B) ratio in mrq is 6.74. Its current Enterprise Value per Revenue stands at 13.115 whereas that against EBITDA is -20.849.
Stock Price History:
The Beta on a monthly basis for SPRY is 0.79, which has changed by -0.058303893 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, SPRY has reached a high of $18.90, while it has fallen to a 52-week low of $6.66. The 50-Day Moving Average of the stock is 7.00%, while the 200-Day Moving Average is calculated to be -21.44%.
Shares Statistics:
According to the various share statistics, SPRY traded on average about 2.25M shares per day over the past 3-months and 1726390 shares per day over the past 10 days. A total of 98.84M shares are outstanding, with a floating share count of 59.73M. Insiders hold about 39.57% of the company’s shares, while institutions hold 63.79% stake in the company. Shares short for SPRY as of 1764288000 were 20664949 with a Short Ratio of 9.18, compared to 1761868800 on 19756847. Therefore, it implies a Short% of Shares Outstanding of 20664949 and a Short% of Float of 34.06.
Earnings Estimates
The performance of ARS Pharmaceuticals Inc (SPRY) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.49 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.75 and -$1.89 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.33, with 4.0 analysts recommending between -$0.92 and -$2.12.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $26.25M. It ranges from a high estimate of $31.9M to a low estimate of $21.8M. As of. The current estimate, ARS Pharmaceuticals Inc’s year-ago sales were $86.58MFor the next quarter, 6 analysts are estimating revenue of $25.32M. There is a high estimate of $29M for the next quarter, whereas the lowest estimate is $21M.
A total of 6 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $88.1M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $82.38M. In the same quarter a year ago, actual revenue was $89.15MBased on 6 analysts’ estimates, the company’s revenue will be $183.28M in the next fiscal year. The high estimate is $236M and the low estimate is $151M.
